ID   CBC2T-2
AC   CVCL_E7BV
DR   CCRID; 4201PAT-CCTCC02244
RX   Patent=CN117004571B;
RX   PubMed=38077157;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2022273.
CC   Population: Chinese.
CC   Doubling time: 47.11 hours (PubMed=38077157).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Extrahepatic bile duct; UBERON=UBERON_0003703.
ST   Source(s): Patent=CN117004571B; PubMed=38077157
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D12S391: 19,20
ST   D13S317: 8,11
ST   D16S539: 9
ST   D18S51: 13
ST   D19S433: 13
ST   D21S11: 30,31.2
ST   D2S1338: 19,22
ST   D2S441: 11,12
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D6S1043: 12,18
ST   D7S820: 9,10
ST   D8S1179: 14,15
ST   FGA: 23,23.2
ST   Penta D: 9,11
ST   Penta E: 12,14
ST   TH01: 9
ST   TPOX: 10,11
ST   vWA: 17,18
DI   NCIt; C208025; Extrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   Patent=CN117004571B;
RA   Meng W.-B., Jiang N.-Z., Bai M.-Z., Huang C.-F.;
RT   "A human hilar cholangiocarcinoma sarcoma cell line CBC2T-2 and its
RT   application.";
RL   Patent number CN117004571B, 05-Nov-2024.
//
RX   PubMed=38077157; DOI=10.3748/wjg.v29.i41.5683; PMCID=PMC10701331;
RA   Jiang N.-Z., Bai M.-Z., Huang C.-F., Ma Z.-L., Zhong R.-Y., Fu W.-K.,
RA   Gao L., Tian L., Mi N.-N., Ma H.-D., Lu Y.-W., Zhang Z.-A., Zhao J.-Y.,
RA   Yu H.-Y., Zhang B.-P., Zhang X.-Z., Ren Y.-X., Zhang C., Zhang Y.,
RA   Yue P., Lin Y.-Y., Meng W.-B.;
RT   "First report on establishment and characterization of the
RT   extrahepatic cholangiocarcinoma sarcoma cell line CBC2T-2.";
RL   World J. Gastroenterol. 29:5683-5698(2023).
//